Myelofibrosis Clinical Trials
Myelofibrosis clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for myelofibrosis. Corterve aggregates actively recruiting Myelofibrosis studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Myelofibrosis studies
- A Study of Ruxolitinib in Combination With Ulixertinib in People With MyelofibrosisNCT06773195PHASE1, PHASE2Memorial Sloan Kettering Cancer CenterBoston, Massachusetts
- Quantitative MRI for MyelofibrosisNCT01973881University of Michigan Rogel Cancer CenterAnn Arbor, Michigan
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsNCT07469891PHASE1Prelude TherapeuticsDenver, Colorado
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell TransplantNCT07020533PHASE1City of Hope Medical CenterDuarte, California
- A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking RuxolitinibNCT07623161PHASE3TakedaGlendale, California
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant DisordersNCT04644016PHASE2Memorial Sloan Kettering Cancer CenterNew York, New York
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)NCT07357727PHASE3Novartis PharmaceuticalsBerkeley Heights, New Jersey
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisNCT05371964PHASE1Geron CorporationDuarte, California
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806PHASE2Karyopharm Therapeutics IncDuarte, California
- Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionNCT06218628PHASE1Fox Chase Cancer CenterPhiladelphia, Pennsylvania
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesNCT07228624PHASE2Fred Hutchinson Cancer CenterSeattle, Washington
- Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary MyelofibrosisNCT04370301PHASE2Fred Hutchinson Cancer CenterSeattle, Washington
Myelofibrosis trials by state
Myelofibrosis trials by metro
Frequently asked questions
- How do I find recruiting Myelofibrosis clinical trials?
- Corterve aggregates actively recruiting Myelofibrosis studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
- Are Myelofibrosis clinical trials free to join?
- Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
- Who can take part in a Myelofibrosis clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.